Wealth Enhancement Advisory Services LLC Raises Stake in Masimo Corporation $MASI
Wealth Enhancement Advisory Services LLC significantly increased its stake in Masimo Corporation (NASDAQ:MASI) by 483.7% in Q4, acquiring an additional 9,423 shares to own a total of 11,371 shares valued at approximately $1.56 million. Despite this, Masimo currently holds an average analyst rating of "Reduce" with a target price of $181.17, following several recent downgrades from financial institutions. The medical equipment provider has a market capitalization of $9.59 billion and is trading with a negative P/E ratio of -16.94.
Quinn Emanuel Disqualified from Masimo Board Fight with Founder
A California state court has disqualified Quinn Emanuel Urquhart & Sullivan LLP from representing Masimo Corp. directors in a lawsuit against former CEO Joe Kiani. The disqualification stems from the firm's prior representation of both Masimo and Kiani in an earlier case, without obtaining Kiani's informed consent to represent the company against him in subsequent litigation. This decision impacts one of several ongoing legal battles between the medical technology company and its founder.
Quinn Emanuel Disqualified from Masimo Board Fight with Founder
A California state court judge has disqualified Quinn Emanuel Urquhart & Sullivan LLP from representing Masimo Corp. directors in a lawsuit brought by its founder, Joe Kiani. The judge ruled that Masimo's board failed to obtain Kiani's informed consent for the law firm's dual representation in previous related litigation. This decision highlights the complexities of conflicts of interest in high-stakes corporate disputes and means Masimo will need to secure new legal counsel.
Masimo Corp Stock: Innovative Medical Tech Leader with Strong Growth Potential for North American In
Masimo Corp is highlighted as a leading innovator in noninvasive patient monitoring, offering robust growth potential for North American investors. The article details its core business model, technological leadership in pulse oximetry and advanced sensors, and strong market positioning against competitors. It also covers the company's financial health, innovation pipeline, and strategic outlook, while acknowledging risks inherent in the medtech industry.
Assenagon Asset Management S.A. Grows Stock Holdings in Masimo Corporation $MASI
Assenagon Asset Management S.A. significantly increased its stake in Masimo Corporation (NASDAQ:MASI) by 2,078.5% in the fourth quarter of the previous year. Other institutional investors, including Viking Global Investors LP and Squarepoint Ops LLC, also increased their exposure to Masimo. Despite increased institutional ownership, several analysts have downgraded Masimo to a "Hold" or "Sell" rating, with a consensus target price of $181.17.
Danaher to Acquire Masimo Diagnostics in $9.9B Deal
Danaher Corp. announced its acquisition of Masimo Corp. for $9.9 billion, including debt, in a deal set to significantly impact the global diagnostics sector. Danaher will pay $180 per share in cash, with Masimo operating as a standalone unit within Danaher's diagnostics segment post-acquisition. The transaction, expected to close in the second half of 2026, aims to integrate Masimo's patient monitoring technologies and expand its global reach.
The Vanguard Group discloses 0 shares in Masimo Corp (NASDAQ: MASI)
The Vanguard Group has filed an Amendment No. 12 to its Schedule 13G/A, reporting zero beneficial ownership of Masimo Corp (NASDAQ: MASI) common stock, equating to 0% of the company. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report their ownership separately, as per SEC Release No. 34-39538. Previously, these subsidiaries' holdings were aggregated with The Vanguard Group.
Masimo Corporation $MASI Shares Sold by JPMorgan Chase & Co.
JPMorgan Chase & Co. decreased its holding in Masimo Corporation (NASDAQ:MASI) by 21.8% in the third quarter, selling 30,149 shares and retaining 107,941 shares valued at $15.93 million. Despite Masimo trading near its 52-week high, the company currently holds a "Hold" consensus rating from Wall Street analysts with an average price target of $181.17. The medical technology company, known for its noninvasive monitoring solutions, has a market capitalization of $9.5 billion and a negative P/E ratio, indicating ongoing losses.
Masimo Corporation (NASDAQ:MASI) Receives Average Recommendation of "Hold" from Brokerages
Masimo Corporation (NASDAQ:MASI) has received an average "Hold" recommendation from nine analysts, with an average 1-year price target of $181.17. Recent downgrades from firms like BTIG, Wolfe Research, and Piper Sandler suggest waning analyst enthusiasm, and the company's shares trade at $176.89 with a market cap of $9.5 billion. Institutional investors hold a significant portion of the company's stock, with some recent large acquisitions.
MASI PE Ratio & Valuation, Is MASI Overvalued
Masimo Corp (MASI) is considered undervalued based on its current forward PE ratio of 22.26 compared to its five-year average of 38.37. The fair price for MASI is estimated to be between $197.20 and $365.74, suggesting it is currently 9.69% undervalued relative to its market price of $178.09. However, its Price-to-Sales (P/S) ratio of 4.27 is significantly above the industry average, which the analysis suggests might be unsustainable given its revenue growth.
Tudor Investment Corp ET AL Buys New Holdings in Masimo Corporation $MASI
Tudor Investment Corp ET AL has acquired a new position in Masimo Corporation (NASDAQ:MASI), purchasing 31,641 shares valued at approximately $4.67 million. This makes Tudor Investment Corp ET AL a 0.06% owner of Masimo. Other institutional investors like Vanguard Group Inc., Massachusetts Financial Services Co. MA, State Street Corp, Westfield Capital Management Co. LP, and Alyeska Investment Group L.P. have also increased their holdings in the medical equipment provider during recent quarters.
Danaher said to near $10 billion deal for Masimo, FT reports
Danaher is reportedly close to acquiring Masimo in a deal valued at nearly $10 billion, according to the Financial Times. This potential acquisition highlights Danaher's continued expansion in the healthcare and life sciences sectors. The deal would significantly impact Masimo's market position, potentially providing it with greater resources and reach.
Masimo's Latest Health Monitoring Receivers Advance Wearable Audio Integration for DACH Consumers
Masimo has launched new health-focused audio receivers that combine high-fidelity audio with vital sign monitoring, targeting European consumers, particularly in Germany, Austria, and Switzerland (DACH region). These devices integrate hospital-grade sensor technology for continuous oxygen saturation and heart rate tracking, alongside premium audio features like Dolby Atmos and DTS:X, aiming to meet the rising demand for multifunctional wellness tech. The company is positioning itself in the growing market for hybrid devices that blend entertainment with health tracking, leveraging its medical technology expertise for consumer applications.
Masimo (NASDAQ:MASI) Upgraded at Wells Fargo & Company
Wells Fargo & Company upgraded Masimo (NASDAQ:MASI) to a "hold" rating, though the stock's consensus rating remains "Hold" with an average price target of $181.17, following several recent downgrades from other firms. Masimo is currently trading near its 1-year high at around $176 with a market cap of $9.46 billion, and institutional investors own approximately 85.96% of the company's stock. The medical technology company specializes in noninvasive monitoring solutions, including its flagship Masimo SET® technology for pulse oximetry.
Masimo (NASDAQ:MASI) Sees Large Volume Increase - Time to Buy?
Masimo (NASDAQ:MASI) experienced a 24% increase in trading volume, with 2,009,264 shares traded, closing at $175.5250. Despite this activity, Wall Street analysts largely maintain a "Hold" rating for the company, with a consensus price target of $181.17 following several recent downgrades. Masimo, a medical technology company specializing in noninvasive monitoring solutions, has a market cap of $9.44 billion and 85.96% institutional ownership.
Masimo (MASI) CFO exercises RSUs, retains shares after tax withholding
Masimo Corp's CFO, Micah W. Young, exercised 873 restricted stock units (RSUs) on March 11, 2026, which is the first 25% vesting of a 3,495-unit grant from March 2025. After 471 shares were withheld for tax obligations at $175.47 per share, he retained the net shares, now directly holding 25,656 shares of Masimo common stock and 2,622 unvested RSUs. This transaction indicates a retention strategy rather than an open-market sale, with the filing noting a neutral impact and sentiment.
Masimo Corporation stock hits 52-week high at $175.91 By Investing.com
Masimo Corporation's stock reached a new 52-week high of $175.91, reflecting significant investor confidence with a 34.86% year-to-date surge. Despite this strong performance, an InvestingPro analysis suggests the stock might be overvalued relative to its Fair Value. The company recently reported strong preliminary financial results for Q4 and full-year 2025, and also saw affiliated leadership changes at Clairity.
Politan-linked funds structure MASIMO (MASI) forward sales over 273,550 shares
Politan-linked entities have entered into two forward sale contracts involving over 273,550 shares of Masimo (MASI). These contracts, dated March 11 and March 12, 2026, provide an upfront payment to Politan Capital Partners Master Fund LP while pledging the shares, with the fund retaining dividend and voting rights and having options for cash or physical settlement at maturity in August 2026. Quentin Koffey, a Masimo board member, and other Politan entities are deemed beneficial owners but disclaim ownership beyond their pecuniary interest.
Masimo Corporation $MASI Shares Purchased by Squarepoint Ops LLC
Squarepoint Ops LLC significantly increased its stake in Masimo Corporation (NASDAQ: MASI) during the third quarter of 2025, boosting its holdings by 738.8% to own 620,932 shares valued at approximately $91.62 million. This move is part of a broader trend of institutional investors, including Royal Bank of Canada and AQR Capital Management, increasing their positions in Masimo, with institutional ownership now standing at 85.96%. Masimo's stock is currently trading near its 52-week high, and analysts maintain a consensus "Hold" rating with an average target price of $181.17.
[Form 4] MASIMO CORP Insider Trading Activity
Catherine M. Szyman, CEO and Director of MASIMO CORP (MASI), reported the acquisition of 39,904 restricted stock units (RSUs) on March 6, 2026, as detailed in a Form 4 SEC filing. These RSUs represent the right to receive one share of common stock each and will vest in four equal annual installments starting from the grant date. Following this transaction, Szyman directly owns all 39,904 RSUs.
12,025 Shares in Masimo Corporation $MASI Bought by Quantitative Investment Management LLC
Quantitative Investment Management LLC has acquired a new stake of 12,025 shares, valued at approximately $1.77 million, in Masimo Corporation (NASDAQ:MASI) during the third quarter. Institutional investors and hedge funds now collectively own about 85.96% of the company's stock. Despite recent downgrades from several firms, including Wells Fargo and Piper Sandler, which have set an average target price of $181.17, Masimo's stock is currently trading near its 52-week high around $175.50.
Masimo (MASI) grants 5,985 restricted stock units to Chief HR Officer
Masimo Corporation's Chief Human Resources Officer, Elisabeth A. Hellmann, was granted 5,985 restricted stock units (RSUs) on March 6, 2026. This equity award vests in four equal annual installments, aligning her compensation with the company's long-term performance. Following this grant, Hellmann directly holds 5,985 RSUs.
Schroder Investment Management Group Has $48.12 Million Holdings in Masimo Corporation $MASI
Schroder Investment Management Group reduced its stake in Masimo Corporation (NASDAQ:MASI) by 24.9% in the third quarter of 2025, holding 336,650 shares worth $48.12 million. Despite this, other institutional investors increased their positions. Analyst consensus for Masimo is currently "Hold" with a price target of $181.17, as the stock trades near its 12-month high with a negative P/E ratio.
6,812 Shares in Masimo Corporation $MASI Bought by Fieldview Capital Management LLC
Fieldview Capital Management LLC has acquired 6,812 shares of Masimo Corporation (NASDAQ:MASI) in the third quarter, a new position valued at approximately $1.005 million. This purchase is part of broader institutional investor activity, with over 85% of Masimo's stock now owned by institutions and hedge funds. Despite recent analyst downgrades, the company holds an average "Hold" rating with a target price of $181.17 from Wall Street analysts.
American Century Companies Inc. Boosts Position in Masimo Corporation $MASI
American Century Companies Inc. increased its stake in Masimo Corporation by 10.6% in the third quarter of 2025, now owning 168,341 shares worth approximately $24.84 million. Other institutional investors like Viking Global, Westfield Capital Management, and Massachusetts Financial Services also made significant moves in Masimo stock. Despite increased institutional ownership (85.96%), analysts generally maintain a "Hold" rating on Masimo, with several recent downgrades and a consensus target price of $181.17.
GW&K Investment Management LLC Boosts Stock Holdings in Masimo Corporation $MASI
GW&K Investment Management LLC significantly increased its stake in Masimo Corporation (NASDAQ:MASI) by 91,786.7% in Q3, now holding 124,047 shares valued at approximately $18.3 million. Other institutional investors like Victory Capital and American Century also adjusted their positions, with institutional ownership totaling about 85.96%. Analysts currently maintain a "Hold" rating for Masimo with an average price target of $181.17, despite recent downgrades.
Picton Mahoney Asset Management Sells 32,587 Shares of Masimo Corporation $MASI
Picton Mahoney Asset Management significantly reduced its stake in Masimo Corporation (NASDAQ:MASI) by 73.1% in the third quarter, selling 32,587 shares and retaining 11,970 shares valued at approximately $1.77 million. Despite this, other institutions like Westfield Capital Management and Jupiter Asset Management increased or initiated substantial positions in Masimo. The medical equipment provider currently has a market capitalization of $9.42 billion, a negative P/E ratio, and analysts maintain a consensus "Hold" rating with an average target price of around $181.
Masimo Corporation $MASI Shares Sold by JPMorgan Chase & Co.
JPMorgan Chase & Co. reduced its stake in Masimo Corporation (NASDAQ:MASI) by 21.8% in the third quarter, selling 30,149 shares and ending with 107,941 shares valued at approximately $15.93 million. Analyst sentiment for Masimo has shifted, with several firms downgrading the stock to a "Hold" rating, resulting in a consensus target price of $181.17. The medical equipment provider's stock is currently trading around $175.36, with a market capitalization of $9.42 billion and a negative P/E ratio.
Joe Kiani Appointed to Scripps Research Board of Directors
Masimo Corp. Founder Joe Kiani has been appointed to the board of directors of Scripps Research, a non-profit biomedical research institute. In this role, Kiani will help guide the institution's strategy in advancing biomedical discovery and translational research. This is one of several board appointments for Kiani recently, following his new company launch, Willow Laboratories, focused on preventing Type 2 diabetes.
Joe Kiani’s Patient Safety Foundation Holds 12th Annual Summit
Joe Kiani's Patient Safety Movement Foundation (PSMF) held its 12th annual summit, focusing on efforts to reduce preventable hospital deaths and featuring former First Lady Jill Biden. The summit highlighted a pilot program in 700 hospitals implementing safety protocols from a 2023 PCAST report. Kiani also provided updates on his other ventures, Willow Laboratories and Like Minded Labs, and his roles on various healthcare company boards.
Masimo Corporation (NASDAQ:MASI) Receives Consensus Rating of "Hold" from Brokerages
Masimo Corporation (NASDAQ:MASI) has received a consensus "Hold" rating from brokerages, with one analyst recommending a sell, seven a hold, and one a buy. The average one-year price target is $181.17, while the stock is currently trading around $175.35, above its 50- and 200-day moving averages. Institutional investors hold a significant portion of the company's shares.
Danaher (NYSE: DHR) to acquire Masimo; MASI proxy materials sent to stockholders
Masimo Corporation and Danaher Corporation have initiated proxy solicitations for Danaher's proposed acquisition of Masimo. Both companies have filed relevant SEC materials, and Masimo will mail a definitive proxy statement and card to its stockholders for approval. The acquisition is subject to customary conditions, including stockholder approval and regulatory clearances, with the timing and completion dependent on these events.
Masimo (MASI) CFO gets performance stock; 1,123 shares withheld for taxes
Masimo Corp's CFO, Micah W. Young, received 2,034 shares of common stock upon the vesting of performance-based restricted stock units, which met three-year performance goals. To cover tax withholding obligations, 1,123 shares were withheld by Masimo at $175.22 per share. Following these transactions, Young directly holds 18,347 shares of Masimo common stock.
Erste Asset Management GmbH Purchases 68,000 Shares of Masimo Corporation $MASI
Erste Asset Management GmbH increased its stake in Masimo Corporation (NASDAQ:MASI) by 73.9% in the third quarter, acquiring an additional 68,000 shares to bring its total holdings to 160,000 shares valued at $22.87 million. Other institutional investors also adjusted their positions in Masimo. Analyst ratings for MASI are predominantly "Hold," with an average target price of $181.17, while the stock currently trades at $175.22.
Masimo Corp. Experiences Evaluation Revision Amid Mixed Market Signals and Volatility
Masimo Corp., a small-cap pharmaceutical and biotechnology company, has undergone an evaluation revision due to mixed market dynamics, with its stock currently trading at $175.22. The company has shown significant price volatility over the past year, with a 52-week high of $194.88 and a low of $125.94. While technical indicators like MACD and Bollinger Bands show some bullish signals, its yearly return of -8.01% significantly underperforms the S&P 500's 12.95% gain, highlighting ongoing market challenges.
Danaher said to near $10 billion deal for Masimo, FT reports
A report indicates that Danaher is nearing a deal to acquire Masimo for a reported $10 billion. This potential acquisition would represent a significant transaction in the medical technology sector.
Uncovering Potential: Masimo's Earnings Preview
Masimo (NASDAQ: MASI) is set to release its quarterly earnings report on Thursday, February 26, 2026, with analysts anticipating an EPS of $1.49. The company's past performance shows it has often beaten EPS estimates, but this has sometimes been followed by a drop in share price. Long-term shareholders may be concerned as the stock has been down 5.77% over the last 52 weeks.
Vanguard Group Inc. Has $709.72 Million Holdings in Masimo Corporation $MASI
Vanguard Group Inc. has significantly increased its stake in Masimo Corporation (NASDAQ:MASI) by 3.7%, now holding over 4.8 million shares valued at approximately $709.72 million. Other institutional investors like Massachusetts Financial Services and State Street also boosted their positions, indicating strong institutional confidence with 85.96% of the company's stock owned by such entities. Despite this, Masimo currently holds a consensus "Hold" rating from analysts with an average price target of $181.17, following recent downgrades from Piper Sandler and Wells Fargo.
Masimo agrees $10BN Danaher switch
Danaher, a biotechnology and diagnostics company, is set to acquire Masimo Corporation, known for its optical pulse oximetry devices, in a deal valued at nearly $10 billion. Masimo will operate as a standalone business unit within Danaher's diagnostics segment, aiming to expand its global reach and accelerate innovation in patient monitoring. This acquisition follows a period of significant change for Masimo, including a leadership transition and a patent infringement win against Apple.
Jupiter Asset Management Ltd. Acquires New Shares in Masimo Corporation $MASI
Jupiter Asset Management Ltd. has acquired a new stake of 84,657 shares, valued at approximately $12.49 million, in Masimo Corporation during the third quarter, representing about 0.16% ownership. Despite this acquisition, analysts have become more cautious, with several downgrades leading to a consensus "Hold" rating and an average price target of $181.17 for Masimo. The company is currently trading near $175.10, with institutional investors holding around 85.96% of its stock.
Danaher to Acquire Masimo in Transaction Valued at $9.9 Billion
Danaher Corporation has entered into a definitive agreement to acquire Masimo Corporation for $180 per share in cash, valuing the transaction at approximately $9.9 billion. Masimo, known for its pulse oximetry and patient monitoring technologies, will operate as a standalone company within Danaher’s Diagnostics segment upon closing. The acquisition is expected to enhance Danaher’s diagnostic capabilities and generate over $530 million in EBITDA for Masimo by 2027.
Masimo's Board Backs Danaher's $9.9B Cash Acquisition Proposal
Masimo's board has unanimously approved a definitive agreement to be acquired by Danaher for $9.9 billion in cash, with Danaher offering $180 per Masimo share. The acquisition is expected to close in the second half of 2026 and will see Masimo operate as a standalone unit within Danaher’s Diagnostics segment, enhancing Danaher's acute care portfolio. This deal follows a period where Masimo explored various opportunities, including a significant drop in share price after controversial acquisitions and an ongoing patent lawsuit with Apple.
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Masimo Corporation - MASI
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Masimo Corporation (NasdaqGS: MASI) to Danaher Corporation (NYSE: DHR) for $180.00 per share in cash. The law firm is examining whether this consideration and the process leading to the transaction adequately value Masimo. Shareholders who believe the Company is undervalued are encouraged to contact KSF to discuss their legal rights.
Masimo Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Masimo Corporation - MASI
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Masimo Corporation to Danaher Corporation for $180.00 cash per share. KSF aims to determine if this price and the sale process are adequate or if the company is undervalued. The law firm is inviting Masimo shareholders to contact them to discuss their legal rights regarding the proposed transaction.
This Masimo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts have changed their outlook on several companies, resulting in five downgrades for Wednesday. Masimo Corp (NASDAQ: MASI) was downgraded from Buy to Neutral by a BTIG analyst, while Toro Co (NYSE: TTC) was downgraded from Outperform to Market Perform by a Raymond James analyst. Other companies receiving downgrades include Genuine Parts Co (NYSE: GPC), AtriCure Inc (NASDAQ: ATRC), and Transocean LTD (NYSE: RIG).
Danaher buys patient monitoring specialist Masimo in $9.9B deal
Danaher Corporation has announced the acquisition of Masimo, a patient monitoring medtech company, for $9.9 billion. Masimo will operate as a standalone company within Danaher's diagnostics segment, strengthening Danaher's portfolio with advanced sensor technology and AI-enabled monitoring. This acquisition follows a period of challenges for Masimo, including a proxy fight and a legal battle with Apple over patent infringement, and is expected to accelerate growth for Danaher’s diagnostics segment.
Masimo (MASI) Climbs 34% on $9.9-Billion Danaher Merger
Masimo Corporation (MASI) saw its shares jump over 34% after announcing a definitive agreement to be acquired by Danaher Corporation for $9.9 billion, or $180 per share. The acquisition price represents a 38.3% premium over Masimo's closing price on February 13. Masimo will continue to operate as a standalone business unit within Danaher’s Diagnostics segment upon the transaction's expected closing in the second half of the year.
Danaher Corp to acquire Masimo for $9.9B
Danaher Corp announced its acquisition of Masimo Corp for $9.9 billion, including debt, at $180 per share. This move aims to strengthen Danaher's diagnostics portfolio with Masimo's leadership in pulse oximetry and patient monitoring solutions. The acquisition is expected to be accretive to Danaher’s earnings and generate significant synergies, with the transaction anticipated to close in the second half of 2026.
Masimo to Be Acquired by Danaher in $180-Per-Share All-Cash Merger
Masimo announced it will be acquired by Danaher for $180.00 per share in an all-cash merger, making Masimo a wholly-owned subsidiary. The transaction requires Masimo stockholder approval, regulatory clearances, and other conditions, with Politan Capital Management already agreeing to vote its shares in favor. Upon completion, Masimo shares will be delisted from Nasdaq.
Danaher Deal Finalized: Company To Acquire Masimo For $9.9 Billion In Cash
Danaher Corporation has finalized a deal to acquire Masimo Corporation for $9.9 billion in an all-cash transaction, paying $180 per share. This acquisition is expected to strengthen Danaher's Diagnostics segment, adding to its adjusted earnings per share and allowing Masimo to operate as a standalone business within Danaher. The deal, anticipated to close in the second half of 2026, aims to deliver strategic growth, financial benefits, and significant synergies.
